CJC-1295 (without DAC) + Ipamorelin

A blend pairing CJC-1295 with Ipamorelin for studying growth-hormone-releasing pathways and secretagogue signalling together.

Supplied as a research-use-only preparation from a cGMP-compliant, ISO-certified facility and guaranteed to a minimum of 99% purity. Each lot is submitted for independent third-party analysis, and the certificate of analysis is tied to the lot code printed on the vial you receive.

Not for human or animal consumption. This compound is intended strictly for in-vitro laboratory and scientific research use. It is not approved by the FDA and is not for medical, diagnostic, or therapeutic use.

Form

Lyophilized powder

Lyophilized storage

Keep dry and sealed. Store per the vial label; protect from light.

Solvent

Bacteriostatic water (0.9% benzyl alcohol)

Reconstituted storage

Refrigerate after reconstitution. Do not shake — swirl to dissolve.

Handling

Allow the vial to reach room temperature before opening to limit condensation.

Category

GHRH / GHRP

Class

Blend pairing CJC-1295 with Ipamorelin

SKU

CJCIPA-10

Purity

≥99% guaranteed

CJC-1295

C165H269N47O46 · 3647.2 g/mol

Ipamorelin

C38H49N9O5 · 711.9 g/mol

Origin

Manufactured in the USA

Availability

In stock

CJC-1295 is a modified GHRH analog engineered for extended half-life. Ipamorelin is a selective agonist at the growth hormone secretagogue receptor (GHS-R), the ghrelin receptor.

Literature examines the growth hormone axis through two distinct receptor routes — the GHRH receptor and the ghrelin receptor.

On the evidence base. Peer-reviewed literature on CJC-1295 specifically is limited; much of what exists is in anti-doping analytical chemistry rather than pharmacology. The references below are reviews that discuss it in that broader context.